Literature DB >> 9727544

Randomized, double-blind crossover study to investigate the effects of amlodipine and isosorbide mononitrate on the time course and severity of exercise-induced myocardial stunning.

C A Rinaldi1, A Z Linka, N D Masani, P G Avery, E Jones, H Saunders, R J Hall.   

Abstract

BACKGROUND: Myocardial stunning may cause prolonged left ventricular dysfunction after exercise-induced ischemia that can be attenuated by calcium antagonists in animal models. To assess their effects in humans, we performed a randomized, double-blind crossover study comparing the calcium antagonist amlodipine (10 mg once daily) versus isosorbide mononitrate (ISMN, 50 mg once daily) on postexercise stunning. METHODS AND
RESULTS: Twenty-four men with chronic stable angina and normal left ventricular function underwent serial quantitative exercise stress echocardiography after 3 weeks on each treatment to assess the degree of postexercise stunning with simultaneous sestamibi single-photon emission computed tomography perfusion scans at peak stress to quantify the ischemic burden. Exercise time (P=1), maximum ST depression (P=0.48), and sestamibi single-photon emission computed tomography scores (P=0.17) were unchanged between treatments. Stunning occurred more often with ISMN than amlodipine (82% versus 48%). The global and segmental stress echocardiography parameters of stunning were attenuated in patients while taking amlodipine compared with ISMN. Shortening fractions and ejection fractions were less impaired 30 minutes after exercise in patients receiving amlodipine (3.5+/-1.4% versus 2.5+/-1.4%, P=0.014, and 59.7+/-5.4% versus 54.5+/-8%, P<0.001); similarly, the isovolumic relaxation period was less prolonged with amlodipine (93+/-15.5 versus 106.3+/-14.9 ms, P=0.018).
CONCLUSIONS: Despite comparable levels of ischemia, amlodipine attenuated stunning when compared with ISMN. This beneficial effect may relate to a prevention of the calcium overload implicated in the pathogenesis of stunning.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9727544     DOI: 10.1161/01.cir.98.8.749

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

1.  Myocardial stunning after streptokinase: what is the significance of the Q wave?

Authors:  W Keeble; W Martin; I Hutton
Journal:  Heart       Date:  2000-06       Impact factor: 5.994

Review 2.  Evidence that stunning can be cumulative in man.

Authors:  C Aldo Rinaldi; Roger J C Hall
Journal:  Heart Fail Rev       Date:  2003-04       Impact factor: 4.214

3.  Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia.

Authors:  E Barnes; C S Baker; D P Dutka; O Rimoldi; C A Rinaldi; P Nihoyannopoulos; P G Camici; R J Hall
Journal:  Heart       Date:  2000-03       Impact factor: 5.994

Review 4.  Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design.

Authors:  Rosita Zakeri; James A Levine; Gabriel A Koepp; Barry A Borlaug; Julio A Chirinos; Martin LeWinter; Peter VanBuren; Victor G Dávila-Román; Lisa de Las Fuentes; Prateeti Khazanie; Adrian Hernandez; Kevin Anstrom; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2015-01       Impact factor: 8.790

Review 5.  Drug treatment of stable angina pectoris in the elderly: defining the place of calcium channel antagonists.

Authors:  Sanjay Kumar; Roger J C Hall
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 6.  Myocardial stunning in man.

Authors:  Edward Barnes; Masood A Khan
Journal:  Heart Fail Rev       Date:  2003-04       Impact factor: 4.214

Review 7.  Preconditioning in humans.

Authors:  Shereif H Rezkalla; Robert A Kloner
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

Review 8.  Amlodipine as an antiischemic drug is superior to long acting nitrates.

Authors:  Goran P Koraćević; Sonja S Dakić; Radmila M Veličković-Radovanović; Svetlana R Apostolović; Nebojša H Krstić; Ivan S Tasić; Marija D Zdravković; Nebojša M Antonijević; Goran N Damnjanović; Tomislav L Kostić
Journal:  Open Med (Wars)       Date:  2014-11-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.